Being aware of the persistently high mortality rate associated with sepsis and septic shock, despite an imposing and growing armamentarium of potent antibiotics, various adjunctive therapies like intravenous immunoglobulins and granulocyte-macrophage colony stimulating factors were evaluated in the treatment of sepsis and septic shock in the last decades. This evidence concerns the gene CSF2 and Sepsis.